Current state of spinal muscular atrophy in Canada: Practical considerations for clinicians | Webinar report
In partnership with Muscular Dystrophy Canada (MDC), NMD4C delivered its first webinar on April 21, 2020. The topic was the current state of spinal muscular atrophy (SMA) in Canada, with a target audience of neurologists, scientists, physicians, medical trainees/students, and other allied healthcare professionals involved in the care of patients with neuromuscular disease (NMD). The goal was to share knowledge on best practices, current issues, disease diagnosis and management, and possible therapeutic interventions.
Read the webinar report HERE
Topics and speakers:
SMA Clinical Care in the Era of COVID-19
Dr. Jodi Warman Chardon (NMD4C Steering Committee member)
Newborn Screening in Ontario
Dr. Kristin Kernohan, Dr. Alex Mackenzie, Dr. Hugh McMillan (NMD4C Investigator)
Update on Zolgensma for Canada
Dr. Hugh McMillan (NMD4C Investigator)
Update on Risdiplam for Canada
Dr. Craig Campbell (NMD4C Investigator)
Adult Outcome Measures
Dr. Colleen O’Connell
Update on CNDR-SMA Project
Dr. Lawrence Korngut (NMD4C Investigator), Dr. Victoria Hodgkinson (NMD4C Collaborator)
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.